Skip to main content

Drug Use Following Genetic Testing Among Patients with Cancer

Basic Details
Date Posted
Status
Complete
Medical Product
afatinib dimaleate
BCR-ABL
bosutinib
BRAF
BRCA
cetuximab
cobimetinib fumarate
dabrafenib mesylate
dasatinib
erlotinib HCL
estimated glomerular filtration rate (eGFR)
gefitinib
imatinib mesylate
KRAS
nilotinib HCL
olaparib
osimertinib mesylate
panitumumab
ponatinib HCL
trametinib dimethyl sulfoxide
vemurafenib
Health Outcome(s)
cancer
Description

This project contains three reports. Report 1 contains estimates of drug use among patients with a prior genetic test and/or relevant cancer diagnosis. Report 2 contains estimated distribution of baseline covariates among members receiving various genetic tests: KRAS, BRAF, EGFR, BCR-ABL, and BRCA. Report 3 contains estimates of drug initiation following genetic testing among patients with relevant cancers.The query was run against the Sentinel Distributed Database (SDD) for the time period of January 1, 2013 to December 31, 2015. The request was distributed to 14 Data Partners on June 17, 2016.

Deliverables (3)
Sentinel Modular Program Report: Drug Use Following Genetic Testing Among Patients with Cancer, Report 1 Sentinel Modular Program Report: Drug Use Following Genetic Testing Among Patients with Cancer, Report 2 Sentinel Modular Program Report: Drug Use Following Genetic Testing Among Patients with Cancer, Report 3
Additional Details
FDA Center
CDER
Time Period
January 1, 2013 - December 31, 2015
Analysis Type
Descriptive
Population / Cohort
All individuals
Data Sources
Sentinel Distributed Database (SDD)
Related Links
Sentinel Drug Study: Pharmacogenetic Testing & Characteristics and Metrics